Consolidated operating revenue increased 10% YoY to Rs 4,336 crore, driven by strong growth in the Biopharma business.
Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal first quarter ended June 30, 2026.
Financial Performance:
- Consolidated operating revenue increased 10% YoY to Rs 4,336 crore, driven by strong growth in the Biopharma business.
- Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets.
- Biosimilars revenue increased 16% YoY to Rs 2,855 crore.
- Generics revenue increased 21% YoY Rs 760 crore.
- Services revenue decreased 16% YoY to Rs 736 crore due to continued impact of challenges faced last year.
- Consolidated EBITDA stood at Rs 902 crore, with a margin of 21%, supported by improved profitability in the Biopharma business, which helped offset continued challenges in the Services business.
- Interest cost at Rs 213 crore, down 23% YoY from Rs 277 crore, following the actions taken to strengthen Biocon’s balance sheet.
- Net Profit before exceptionals was Rs 145 crore.
“Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market. We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth” Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited.
“Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore. This reflects the strength of our diversified portfolio and disciplined commercial execution. In FY27, we have successfully launched Bosaya and Aukelso (biosimilar Denosumab), Yesafili (biosimilar Aflibercept), and generic Liraglutide, further strengthening our presence in the U.S. market. We also secured regulatory approval from the European Medicines Agency (EMA) for our new drug product fill-finish plant for insulins in Malaysia, unlocking additional manufacturing capacity. Our focus on balance sheet optimization reduced interest costs by 23% year-on-year. We expect growth momentum to accelerate through the year, driving a stronger second-half performance.” Shreehas Tambe, CEO & Managing Director, Biocon Limited.
